The results imply that a gene signature based on CSE1L and AURK pathway gene expression similar to the one we developed here could be used to identify p53 WT NSCLC tumors that will be most sensitive/responsive to mocetinostat plus PTX. This evidence concerns the gene TP53 and non-small cell lung carcinoma.